LUCA Biologics
Living medicines targeting the vaginal microbiome to impact women's health. A Seed Health foundry company.
Living medicines targeting the vaginal microbiome to impact women's health. A Seed Health foundry company.
LUCA Biologics, a **biotechnology** startup, is focused on developing **living medicines** that target the vaginal microbiome to improve women's health. Established in **2019** and headquartered in the **United States**, the company's mission is to address reproductive and urogenital health issues by leveraging metagenomic and metatranscriptomic approaches. Led by Dr. Jacques Ravel, a prominent figure in the vaginal microbiome division of the NIH's Human Microbiome Project, LUCA Biologics' pipeline includes treatments for conditions such as urinary tract infection (UTI), preterm birth (PTB), bacterial vaginosis (BV), and infertility. The company recently secured a **$2.80 million** Seed Round investment on **07 August 2019**, with backing from **Seed Health**, a notable figure in the health tech industry. LUCA Biologics stands out as a promising player in the biotech and healthcare sectors, with a focused approach and support from renowned investors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $2.80M | 1 |
|
07 Aug 2019 |
No recent news or press coverage available for LUCA Biologics.
We care about your data, and we'd love to use cookies make your experience better.
